Starpharma Holdings Limited
SPHRF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.23 | 0.11 | 2.22 | 0.85 |
| FCF Yield | -15.33% | -16.96% | -10.79% | -4.95% |
| EV / EBITDA | -2.87 | -2.27 | -6.12 | -14.50 |
| Quality | ||||
| ROIC | -55.90% | -33.88% | -80.00% | -61.96% |
| Gross Margin | 75.08% | 92.38% | 28.15% | 36.92% |
| Cash Conversion Ratio | – | 0.85 | 0.87 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.19% | 17.10% | 7.59% | -10.14% |
| Free Cash Flow Growth | 3.75% | 50.08% | -1.11% | 7.01% |
| Safety | ||||
| Net Debt / EBITDA | 1.19 | 2.06 | 1.58 | 2.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.64 | 0.26 | 0.62 | 0.98 |
| Cash Conversion Cycle | 272.50 | 96.10 | -124.87 | 36.29 |